Highlights•“Old” molecules and targets represent attractive start points.•Modern medicinal
chemistry is essential to convert a compound hit into a drug.•Nutritional flexibility makes …

Tuberculosis (TB) remains one of the deadliest infectious diseases caused by
Mycobacterium tuberculosis (M. tb). It is responsible for significant causes of mortality and …

Mycobacterium abscessus (Mab), a nontuberculous mycobacterial (NTM) species, is an
emerging pathogen with high intrinsic drug resistance. Current standard-of-care therapy …

The Nix-TB clinical trial evaluated a new 6 month regimen containing three oral drugs;
bedaquiline (B), pretomanid (Pa), and linezolid (L)(BPaL regimen) for the treatment of …

The spectinamides are novel, narrow-spectrum semisynthetic analogs of spectinomycin,
modified to avoid intrinsic efflux by Mycobacterium tuberculosis. Spectinamides, including …

The emergence of drug-resistant Mycobacterium tuberculosis strains is a threat to global
health necessitating the discovery of novel chemotherapeutic agents. Natural products drug …

Despite reinvigorated efforts in Tuberculosis (TB) drug discovery over the past 20 years,
relatively few new drugs and candidates have emerged with clear utility against drug …

Spectinamides 1599 and 1810 are lead spectinamide compounds currently under
preclinical development to treat multidrug-resistant (MDR) and extensively drug-resistant …

Spectinamides are a novel series of spectinomycin analogs being developed for the
treatment of tuberculosis. The preclinical lead spectinamide 1599 is an antituberculosis drug …

Mycobacterium tuberculosis infection has emerged as a global public health issue,
predominantly manifesting as pulmonary tuberculosis. Bone and joint tuberculosis, with …